A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations

Brief description of study

If you have been diagnosed with intermediate or high risk Myelodysplastic Syndrome with a mutation in the Tet methylcytosine dioxygenase (abbreviated as TET) gene, you may be qualified for this Phase Ib/IIa study. The main goal of this study is to test the safety and to see how well a high dose of vitamin C works in subjects with high risk Myelodysplastic Syndrome.

Clinical Study Identifier: s17-00978
ClinicalTrials.gov Identifier: NCT03433781
Principal Investigator: Mohammad Maher Abdul Hay.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.